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C4BP = C4-binding protein; EPCR = endothelial cell Protein C receptor; PAI = plasminogen activator inhibitor; TF = tissue factor; TNF = tumor
necrosis factor.
Available online http://ccforum.com/content/5/S2/S7
Introduction
The initiation of coagulation, especially in severe sepsis, is
probably mediated by the induction of tissue factor (TF)
expression by endotoxin. This leads to the activation of
factor X, which then combines with factor Va to convert
prothrombin to thrombin. Although thrombin is usually
considered to have purely procoagulant activity, it is in fact
a multifunctional protein that has some important homeo-
static anticoagulant effects (Fig. 1) [1]. One of its main
functions is to bind to thrombomodulin, which is
expressed on the endothelial cell surface. Thrombomod-
ulin is the major physiologic buffer for the procoagulant
effects of thrombin in normal vessels [2,3]. Because
thrombomodulin binds to the same site on thrombin that
would normally bind to fibrinogen, platelets or factor V, all
of these functions are blocked. Instead, the thrombin–
thrombomodulin complex activates Protein C (through a
different site on the thrombin molecule), resulting in initia-
tion of the Activated Protein C pathway [3]. This process
is augmented by the EPCR [4,5]. Activated Protein C
must dissociate from EPCR before it can bind to Protein S
and function as an effective anticoagulant through the
inactivation of factor Va.
Thrombomodulin and Activated Protein C in
the microcirculation
Activated Protein C is particularly important in the micro-
circulation [3]. Although the number of thrombomodulin
molecules per endothelial cell is approximately constant,
the local concentration of thrombomodulin is determined
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by the number of endothelial cells that are in contact with
the blood. Because the endothelial cell surface area per
unit blood volume is much greater in the microcirculation
(approximately 3000–5000 cm2 of endothelium/ml blood)
than in larger blood vessels (approximately 1.5 cm2/ml)
(Fig. 2) [6], there is a correspondingly high concentration
of thrombomodulin in the normal microvasculature
(approximately 500 nmol/l) as compared with the larger
vessels (approximately 0.1–0.2 nmol/l). As a result, throm-
bin is rapidly removed from the microcirculation as it is
bound to thrombomodulin. This suggests that the Acti-
vated Protein C system is uniquely poised to regulate
coagulopathies in the microcirculation, and this has been
confirmed in clinical studies [7].
Importantly, at least in some forms of sepsis, thrombomod-
ulin can be downregulated, with resulting loss of ability to
regulate thrombin, and hence clotting, in the microcircula-
tion. Homozygous Protein C deficiency has a similar result,
such that affected babies develop microvascular thrombo-
sis (purpura fulminans) almost immediately after birth
[3,8]. In contrast, antithrombin deficiencies cause large-
vessel thrombosis.
Vicious cycle of coagulation and inflammation
In addition to its procoagulant and anticoagulant effects,
thrombin can also be involved in the process of inflam-
mation (Fig. 1) [1]. That is, it can activate endothelial
cells to express P-selectin, causing neutrophil and mono-
cyte adhesion. It is also chemotactic for polymorphonu-
clear leukocytes and is a potent inducer of endothelial
platelet-activating factor formation. Platelet-activating
factor is a major activator of neutrophils, which have
been demonstrated to play an important role in the
pathogenesis of sepsis.
The inflammatory response also modulates the coagula-
tion system, including downregulation of the expression of
thrombomodulin (Fig. 3) [9]. Inflammation also increases
levels of a1-antitrypsin, which is an acute-phase response
protein and an important inhibitor of the Protein C
pathway. Acute inflammatory mediators such as tumor
necrosis factor (TNF)-a and endotoxin amplify the produc-
tion of TF, particularly by monocytes, triggering further
coagulation. Complement activation by endotoxin
increases exposure of clot-promoting membrane phospho-
lipids to blood, and thereby propagates the coagulation
response. In certain forms of inflammation, levels of both
fibrinogen and plasminogen activator inhibitor (PAI)-1 (an
inhibitor of fibrinolysis) are increased.
If there were no mechanisms to disrupt the amplification of
coagulation by inflammation, and vice versa, then the
ensuing vicious cycle would have a catastrophic effect,
leading ultimately to death (Fig. 4) [10]. It was hypothe-
sized, therefore, that endogenous Activated Protein C
interferes with these amplification loops by modulating
both coagulation and inflammation, which differentiates it
from other types of anticoagulants, and that Protein C
depletion may occur in severe sepsis [11].
A primate model was used in the initial study undertaken
to investigate this possibility [11]. In animals infused with a
lethal Escherichia coli dose alone, Protein C and fibrino-
gen levels fell, liver damage occurred (Fig. 5a), and the
animals died within 24–32 h. In contrast, organ damage
Figure 1
Cellular and humoral responses to nM concentrations of thrombin. EC,
endothelial cell; PAF, platelet-activating factor; PDGF, platelet-derived
growth factor; PMN, polymorphonuclear leukocyte; TGF, transforming
growth factor. Adapted from Esmon [1].
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Figure 2
Endothelial cell surface area per ml of blood. Adapted from Busch et al
[6].
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was prevented in animals given a lethal dose of E. coli
plus an infusion of Activated Protein C (Fig. 5b). Impor-
tantly, it was shown that animals could still be rescued if
Activated Protein C was given 2–3 h after the lethal E. coli
dose was administered. Similarly, when animals were
given a sublethal dose of E. coli and Protein C activation
was blocked with an antibody, mimicking the clinical situa-
tion in a patient with sepsis and low Protein C levels, the
sublethal bacterial dose became lethal, with complete fib-
rinogen consumption, a disseminated intravascular coagu-
lation-like syndrome, organ failure, and a full-blown septic
shock-like response (Fig. 6) [11].
Amplification of the inflammatory mediators in this setting
aggravates the process still further. C4-binding protein
(C4BP) is an acute-phase protein that is known to bind
and inhibit Protein S, a vital cofactor for the Activated
Protein C system. In another primate study [12], it was
shown that administration of C4BP together with a
Figure 4
The inflammation–coagulation autoamplification loop. Adapted from
Esmon et al [10].
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Figure 5
Primate model of sepsis. (a) Lethal E. coli infusion alone. (b) Lethal
E. coli plus Activated Protein C infusion. SGPT, serum glutamic pyruvic
transaminase (indicator of liver damage). Adapted from Taylor et al [11].
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Figure 3
Roles of inflammatory mediators in the coagulation response. Adapted
from Esmon [9].
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(b)normally sublethal dose of E. coli resulted in complete
fibrinogen consumption and death. In the same study, it
was shown that, whereas either sublethal E. coli doses or
C4BP alone had no appreciable effect on TNF-a produc-
tion, administration of both substances led to a circulating
TNF-a level that approached that seen with a lethal dose
of E. coli (Fig. 7), with rapid consumption of fibrinogen,
systemic organ damage, and eventual death. With co-
administration of Protein S, however, TNF-a levels
remained similar to those seen in animals administered a
sublethal dose of E. coli alone (Fig. 7), and all of these
animals survived. This suggests that reversal of the
inhibitory effects of inflammatory cytokines on the Acti-
vated Protein C pathway can control the inflammatory
response.
Activated Protein C can promote fibrinolysis by at least
two mechanisms. One involves the ability of Activated
Protein C to form a tight complex with PAI-1. Once the
complex with Activated Protein C forms, PAI-1 (the major
inhibitor of tissue plasminogen activator) can no longer
inhibit tissue plasminogen activator [13]. Because of the
ability of Activated Protein C to limit thrombin generation,
it can also reduce the activation of a precarboxypeptidase
B commonly referred to as thrombin activatable fibrinolysis
inhibitor [14,15]. Thrombin activatable fibrinolysis inhibitor
functions by removing lysine residues from the fibrin clot
that would normally play a role in augmenting plasminogen
activation and the fibrinolytic activity of plasmin.
The potentially protective effect of Activated Protein C has
also been shown in two rat studies [16,17], both of which
suggested inhibition of leukocyte activation as an impor-
tant mechanism. In one of these studies [16], Activated
Protein C was shown to reduce motor disturbance result-
ing from spinal cord injury by reducing local levels of
TNF-a, thereby inhibiting neutrophil accumulation. In the
other study [17], animals treated with Activated Protein C
were found to have a reduction in ischemia/reperfusion-
induced renal injury, which was associated with reductions
in renal levels of TNF-a, interleukin-8 and myeloperoxidase,
with resulting inhibition of leukocyte activation.
Unique properties of the Activated Protein C
pathway
Activated Protein C has a number of properties that differ-
entiate it from other anticoagulants, such as heparin or
Critical Care    Vol 5 Suppl 2 Esmon
Figure 6
Primate model of sepsis. (a) Sublethal E. coli infusion alone.
(b) Sublethal E. coli plus antiProtein C monoclonal antibody infusion.
HPC4, murine monoclonal antibody to human Protein C; Ig,
immunoglobulin; SGPT, serum glutamic pyruvic transaminase (indicator
of liver damage). Adapted from Taylor et al [11].
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Figure 7
TNF-a production in response to sublethal or lethal E. coli infusion,
with or without C4BP and Protein S (PS) supplementation. C4BP and
PS were administered at doses of 20 mg/kg and 3 mg/kg,
respectively. SLEC, 10% of a lethal dose of E. coli; LEC, 100% lethal
dose dose of E. coli. Adapted from Taylor et al [12].
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(b)antithrombin. First, the Activated Protein C system is
geared to modulate coagulopathy within the microvascula-
ture, and it is microvascular disease that lies at the root of
sepsis. Second, the Activated Protein C system involves
the EPCR, which was identified during research to dis-
cover possible receptors and pathways linked to the
system [17]. The EPCR was found to be homologous to
the major histocompatibility complex class I family of mole-
cules [4], all of which are involved in the regulation of
inflammation.
The Activated Protein C/EPCR-mediated anticoagulant
pathway is illustrated in Fig. 8 [18]. The EPCR is synthe-
sized on the endothelial cell surface and moves to special-
ized regions (caveolae) in the endothelium, through which
it is able to enter the cell and then the cell nucleus. Once
inside the nucleus, it is able to redirect the gene expres-
sion profiles within the cell. Unlike other plasma membrane
receptors, EPCR is also capable of carrying Activated
Protein C into the nucleus, with subsequent alterations to
some of the gene products.
Furthermore, when thrombin or inflammatory cytokines
come into contact with the endothelium, they induce shed-
ding of EPCR from the cell surface, a process that is
mediated by a metalloproteinase [5]. Soluble EPCR binds
to proteinase 3, a serine proteinase that is found in neu-
trophils. This soluble EPCR–proteinase 3 complex, either
alone or in a complex with Protein C, appears to interact
with neutrophils via an integrin (Mac-1) to inhibit their
adhesion to the endothelium, and as a result prevents the
migration of the neutrophils into the tissues [19].
Several unique mechanisms by which Activated Protein C
can affect inflammation and coagulation have been demon-
strated in various in vitro studies [20–23]. In one study [20],
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Figure 8
Activated Protein C/EPCR-mediated anticoagulant pathway. APC, Activated Protein C; MP, metalloproteinase; Palm, palmitate; PC, Protein C;
PMA, phorbol myristate acetate; TM, thrombomodulin; RRC, Arg,Arg,Lys. Adapted from Esmon [18].it was shown that incubation of monocytes with Activated
Protein C leads to a decrease in TNF-a production and
blockade of the translocation and activation of the central
proinflammatory transcription factor nuclear factor-kB in
response to lipopolysaccharide exposure. The binding of
Activated Protein C to a specific receptor on mononuclear
phagocytes has also been shown to inhibit intracellular
calcium signaling and monocyte-dependent T-cell prolifera-
tive responses [21]. Finally, EPCR-dependent TF suppres-
sion by Activated Protein C has been demonstrated in a
human monoblastic leukemia cell line [22].
Conclusion
The sepsis cascade, which is associated with simultaneous
activation of systemic inflammation and coagulation, along
with altered fibrinolysis, leads to microvascular endothelial
injury, acute organ dysfunction, and possibly death. Throm-
bin, with its procoagulant and anticoagulant effects, as well
as its involvement in the process of inflammation, is thought
to be central to the sepsis cascade. In vitro and animal
models suggest that Activated Protein C, a protein that has
antithrombotic, anti-inflammatory and profibrinolytic activi-
ties, may be an important modulator of the vicious cycle of
coagulation and inflammation associated with the sepsis
cascade, which if unchecked may ultimately lead to death.
Several properties of Activated Protein C, including its
unique positioning to regulate coagulopathies in the
microvasculature and the ability of EPCR to facilitate Protein
C activation, support the continued development of Acti-
vated Protein C-mediated strategies that are aimed at dis-
rupting the process whereby inflammation initiates
coagulation and coagulation amplifies inflammation.
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